Literature DB >> 22200082

Targeted catalytic inactivation of angiotensin converting enzyme by lisinopril-coupled transition-metal chelates.

Jeff C Joyner1, Lalintip Hocharoen, J A Cowan.   

Abstract

A series of compounds that target reactive transition-metal chelates to somatic angiotensin converting enzyme (sACE-1) have been synthesized. Half-maximal inhibitory concentrations (IC(50)) and rate constants for both inactivation and cleavage of full-length sACE-1 have been determined and evaluated in terms of metal chelate size, charge, reduction potential, coordination unsaturation, and coreactant selectivity. Ethylenediaminetetraacetic acid (EDTA), nitrilotriacetic acid (NTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and tripeptide GGH were linked to the lysine side chain of lisinopril by 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride/N-hydroxysuccinimide coupling. The resulting amide-linked chelate-lisinopril (EDTA-lisinopril, NTA-lisinopril, DOTA-lisinopril, and GGH-lisinopril) conjugates were used to form coordination complexes with iron, cobalt, nickel, and copper, such that lisinopril could mediate localization of the reactive metal chelates to sACE-1. ACE activity was assayed by monitoring cleavage of the fluorogenic substrate Mca-RPPGFSAFK(Dnp)-OH, a derivative of bradykinin, following preincubation with metal chelate-lisinopril compounds. Concentration-dependent inhibition of sACE-1 by metal chelate-lisinopril complexes revealed IC(50) values ranging from 44 to 4500 nM for Ni-NTA-lisinopril and Ni-DOTA-lisinopril, respectively, versus 1.9 nM for lisinopril. Stronger inhibition was correlated with smaller size and lower negative charge of the attached metal chelates. Time-dependent inactivation of sACE-1 by metal chelate-lisinopril complexes revealed a remarkable range of catalytic activities, with second-order rate constants as high as 150,000 M(-1) min(-1) (Cu-GGH-lisinopril), while catalyst-mediated cleavage of sACE-1 typically occurred at much lower rates, indicating that inactivation arose primarily from side chain modification. Optimal inactivation of sACE-1 was observed when the reduction potential for the metal center was poised near 1000 mV, reflecting the difficulty of protein oxidation. This class of metal chelate-lisinopril complexes possesses a range of high-affinity binding to ACE, introduces the advantage of irreversible catalytic turnover, and marks an important step toward the development of multiple-turnover drugs for selective inactivation of sACE-1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22200082      PMCID: PMC3401419          DOI: 10.1021/ja208791f

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  51 in total

1.  Partial charge calculation method affects CoMFA QSAR prediction accuracy.

Authors:  Ruchi R Mittal; Lisa Harris; Ross A McKinnon; Michael J Sorich
Journal:  J Chem Inf Model       Date:  2009-03       Impact factor: 4.956

2.  Factors influencing the DNA nuclease activity of iron, cobalt, nickel, and copper chelates.

Authors:  Jeff C Joyner; Jared Reichfield; J A Cowan
Journal:  J Am Chem Soc       Date:  2011-09-14       Impact factor: 15.419

3.  Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension.

Authors:  D L Sherman; J F Keaney; E S Biegelsen; S J Duffy; J D Coffman; J A Vita
Journal:  Hypertension       Date:  2000-04       Impact factor: 10.190

4.  Peptide-cleaving catalyst selective for melanin-concentrating hormone: Oxidative decarboxylation of N-terminal aspartate catalyzed by Co(III)cyclen.

Authors:  Min Gyum Kim; Myoung-soon Kim; Seong Du Lee; Junghun Suh
Journal:  J Biol Inorg Chem       Date:  2006-07-13       Impact factor: 3.358

5.  New chelating ligands for Co(III)-based peptide-cleaving catalysts selective for pathogenic proteins of amyloidoses.

Authors:  Woo Suk Chei; Heeyeon Ju; Junghun Suh
Journal:  J Biol Inorg Chem       Date:  2010-12-18       Impact factor: 3.358

6.  Highly specific oxidative cross-linking of proteins mediated by a nickel-peptide complex.

Authors:  K C Brown; S H Yang; T Kodadek
Journal:  Biochemistry       Date:  1995-04-11       Impact factor: 3.162

7.  Naturally occurring active N-domain of human angiotensin I-converting enzyme.

Authors:  P A Deddish; J Wang; B Michel; P W Morris; N O Davidson; R A Skidgel; E G Erdös
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

8.  Neuromedin C binds Cu(II) and Ni(II) via the ATCUN motif: implications for the CNS and cancer growth.

Authors:  C Harford; B Sarkar
Journal:  Biochem Biophys Res Commun       Date:  1995-04-26       Impact factor: 3.575

9.  Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design.

Authors:  Hazel R Corradi; Sylva L U Schwager; Aloysius T Nchinda; Edward D Sturrock; K Ravi Acharya
Journal:  J Mol Biol       Date:  2006-01-31       Impact factor: 5.469

10.  Cellular activity of Rev response element RNA targeting metallopeptides.

Authors:  Yan Jin; J A Cowan
Journal:  J Biol Inorg Chem       Date:  2007-03-14       Impact factor: 3.862

View more
  11 in total

Review 1.  Optochemical Control of Biological Processes in Cells and Animals.

Authors:  Nicholas Ankenbruck; Taylor Courtney; Yuta Naro; Alexander Deiters
Journal:  Angew Chem Int Ed Engl       Date:  2018-02-01       Impact factor: 15.336

2.  Insight into the recognition, binding, and reactivity of catalytic metallodrugs targeting stem loop IIb of hepatitis C IRES RNA.

Authors:  Seth S Bradford; Martin James Ross; Insiya Fidai; James A Cowan
Journal:  ChemMedChem       Date:  2014-04-22       Impact factor: 3.466

3.  Analysis of Structure-Activity Relationships Based on the Hepatitis C Virus SLIIb Internal Ribosomal Entry Sequence RNA-Targeting GGHYRFK⋅Cu Complex.

Authors:  Martin James Ross; Insiya Fidai; James A Cowan
Journal:  Chembiochem       Date:  2017-08-07       Impact factor: 3.164

4.  Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells.

Authors:  Shrinidh Joshi; Narayanaganesh Balasubramanian; Goutham Vasam; Yagna Pr Jarajapu
Journal:  Eur J Pharmacol       Date:  2016-02-03       Impact factor: 4.432

5.  Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability.

Authors:  Md Shafikur Rahman; Shikha Kumari; Shiva Hadi Esfahani; Saeideh Nozohouri; Srinidhi Jayaraman; Nihar Kinarivala; Joanna Kocot; Andrew Baez; Delaney Farris; Thomas J Abbruscato; Vardan T Karamyan; Paul C Trippier
Journal:  J Med Chem       Date:  2021-08-26       Impact factor: 8.039

6.  Antimicrobial metallopeptides with broad nuclease and ribonuclease activity.

Authors:  Jeff C Joyner; W F Hodnick; Ada S Cowan; Deepika Tamuly; Rachel Boyd; J A Cowan
Journal:  Chem Commun (Camb)       Date:  2013-02-05       Impact factor: 6.222

7.  Inactivation of sortase A mediated by metal ATCUN complexes.

Authors:  Insiya Fidai; Lalintip Hocharoen; Seth Bradford; Christine Wachnowsky; J A Cowan
Journal:  J Biol Inorg Chem       Date:  2014-09-09       Impact factor: 3.358

8.  N- versus C-domain selectivity of catalytic inactivation of human angiotensin converting enzyme by lisinopril-coupled transition metal chelates.

Authors:  Lalintip Hocharoen; Jeff C Joyner; J A Cowan
Journal:  J Med Chem       Date:  2013-12-05       Impact factor: 7.446

9.  Identification and Characterization of Two Structurally Related Dipeptides that Enhance Catalytic Efficiency of Neurolysin.

Authors:  Srinidhi Jayaraman; Joanna Kocot; Shiva Hadi Esfahani; Naomi J Wangler; Arzu Uyar; Yehia Mechref; Paul C Trippier; Thomas J Abbruscato; Alex Dickson; Hideki Aihara; David A Ostrov; Vardan T Karamyan
Journal:  J Pharmacol Exp Ther       Date:  2021-08-13       Impact factor: 4.030

Review 10.  Target-directed catalytic metallodrugs.

Authors:  J C Joyner; J A Cowan
Journal:  Braz J Med Biol Res       Date:  2013-07-02       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.